Fondaparinux sodium (Arixtra)
- selectively inhibits factor Xa, disrupting blood coagulation and inhibiting thrombin formation and thrombus development
- availability – 2.5 mg/0.5 ml in single-dose syringe
- indications (non-comprehensive)
- prevention of deep vein thrombosis (DVT) after hip fracture surgery or hip or knee replacement surgery
- DVT and pulmonary emboli
- references - The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.
- Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major orthopaedic surgery. A systematic review.
- Prevention of venous thromboembolic disease after total hip and knee arthroplasty.
- Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.
- Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.
Heparin
XARELTO® (rivaroxaban)
- Information
- highly selective direct factor Xa inhibitor with oral bioavailability and rapid onset of action
- availability – 10 mg, 15 mg, and 20 mg tablets
- indications (non-comprehensive)
- prophylaxis of deep vein thrombosis (DVT) in adults undergoing hip and knee replacement
- treatment of patients with DVT and pulmonary embolism (PE)
- long-term treatment to prevent recurrence of DVT and PE
- how XARELTO® works
- HCP Resources
- dosing and transition management (pdf)
- switching patients to and from XARELTO®
- trial data in patients undergoing total knee or hip replacement (video)
- Download the XARELTO® DocCenter app, available for tablet and mobile device.
- Patient Resources
- ORS patient brochure (pdf)
- References
